Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SNY crawled time : 20:20 save search
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.24%
H: 0.0%
C: -0.8%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.84%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.11%
H: 0.32%
C: -0.07%
response
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
trial potential
New Hybrid Treatment Forces Cancer Cells to Starve
Published: 2023-12-09 (Crawled : 20:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
cancer treatment
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
Published: 2023-10-22 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.48%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.21%
H: 0.08%
C: -1.81%
dupixent children year one results show
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
Published: 2023-10-22 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.73%
H: 0.0%
C: -0.48%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.21%
H: 0.08%
C: -1.81%
dupixent children year one results show
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
Published: 2023-07-29 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
macular trial results diabetic
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
Published: 2023-05-21 (Crawled : 20:20) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.44%
H: 0.75%
C: -1.43%
dupixent copd results
Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine
Published: 2023-05-21 (Crawled : 20:20) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.75%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 0.44%
H: 0.75%
C: -1.43%
dupixent copd results
Sobi to streamline nirsevimab contractual arrangements
Published: 2023-04-09 (Crawled : 20:20) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.7%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.72%
H: 0.0%
C: 0.0%
Global Viscosupplementation Market Report 2022: Sector to Reach $6.27 Billion by 2028 at a 9.1% CAGR
Published: 2023-01-22 (Crawled : 20:20) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
SNNUF | $11.93 -1.12% 710
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
ANIK | $25.84 1.61% 1.59% 49K
|
Health Technology
| Email alert
Add to watchlist
global report market
Press Release: Statement from Sanofi regarding Horizon Therapeutics plc (“Horizon”)
Published: 2022-12-11 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -2.34%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.02%
H: 0.0%
C: 0.0%
therapeutics sanofi
Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO
Published: 2022-06-05 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
| Email alert
Add to watchlist
immunotherapy asco positive cancer pancreatic phase 1
$10.1 billion (€9.1 billion) pledged in new grants and loans as part of the Stand Up for Ukraine Event to support those who have had to flee their homes in Ukraine
Published: 2022-04-09 (Crawled : 20:20) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
Sanofi: Information concerning the total number of voting rights and shares – February 2022
Published: 2022-03-26 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
Published: 2022-02-26 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
dupixent urticaria phase 3 hiv
Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
Published: 2022-02-26 (Crawled : 20:20) - globenewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
dupixent
New Results from ATLAS Phase 3 Program with Fitusiran Presented at ASH Annual Meeting 2021
Published: 2021-12-12 (Crawled : 20:20) - alnylam.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 2.8%
H: 0.0%
C: 0.0%
results phase 3
New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma
Published: 2021-12-11 (Crawled : 20:20) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
regn5458 phase 1
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.